An interview with Elaine Pinheiro, Principal Scientist at MSD, speaker at the Advances in Immuno-oncology Congress, 12-13 May 2016, London, UK
Posted: 13 January 2016 | Oxford Global | No comments yet
Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment…
An Interview with Elaine Pinheiro, Principal Scientist at MSD, Speaker at the Advances in Immuno-oncology Congress, 12-13 May 2016, London, UK Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment. Elaine will be speaking on the second day of the Advances in Immuno-oncology Congress on preclinical strategies to support the development.
Why is this such an exciting time for immuno-oncology at the moment, and what do you expect to see from the industry over the next couple of years?
This is an exciting time in the field. Multiple strategies for eliciting and enhancing anti-tumor immunity have been developed, some of which are currently in the clinic. In particular, immune checkpoint therapy, such as PD-1 blockade, has led to important clinical advances showing significant and durable clinical activity in multiple types of advanced cancers. We predict that the list of cancers sensitive to anti-PD-1 therapy will grow. The field is developing rapidly and currently moving towards combination strategies that can improve upon anti-tumor responses, produce durable clinical benefit, and expand patient populations and indications. We expect to see an expansion of combination strategies with PD-1 blockade as a foundation therapy in combination with other mechanisms. Even the early discovery programs are strategically focused on trying to identify the optimal combination partners with pembrolizumab. This will also require the generation of novel biomarker strategies. For cancer immunotherapy, mechanistic insights will be integral to next-generation biomarker development.
Click here to read the full interview with Elaine.
Taking place on 12-13 May 2016 in central London this is the first industry-focused event of its kind dealing exclusively with immuno-oncology. This congress will feature a panel of leading global experts in the field of cancer immunotherapy who will address the very latest advances in therapeutic approaches, clinical trial data, and collaborations. Speakers will discuss innovations in areas including bispecific antibodies, CAR T therapy, cancer vaccines and combination therapies.
Download the agenda here to view the full line up of speakers and their presentations. Registration
Contact Danielle Dalby today on [email protected] or call +44(0)1865 248455 to secure your place. Early Bird Discounts are available for a limited time.